Do you want to read an article? Please log in or register.
Fourth Swiss Annual Meeting on HER2-Positive Breast Cancer: Antibody-Drug Conjugates in HER2-Positive Disease and Beyond
Breast Cancer
Related content
COMMENTED
Breast Cancer
Sequencing antibody-drug conjugates in metastatic breast cancer: A systematic review
★ 2
Recommended and commented by
Dr Andreas Müller, Faculty Member
★ 1
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
Cancer Treat Rev
de Almeida LFC, Leite LF, Cappellaro AP, da Conceição LD, Noronha MM, da Silva JL, de Melo AC, Batalini F, Tarantino P
doi: 10.1016/j.ctrv.2025.103067
ESMO 2025
Breast Cancer
LBA1: DESTINY-Breast05: T-DXd significantly improves IDFS and DFS versus T-DM1 in HER2-positive early breast cancer with residual invasive disease
Breast Cancer
Impact of trop-2 expression on the efficacy of trop-2-targeted antibody-drug conjugates in metastatic breast cancer: a systematic review and meta-analysis
J Natl Cancer Inst
Buonaiuto R, Pagliuca M, Longobardi A, Cataldo ML, Arecco L, Gerosa R, Gentile G, Caltavituro A, Barone I, Karakose B, Agostinetto E, Sotiriou C, De Laurentiis M, De Azambuja E, De Angelis C
doi: 10.1093/jnci/djag220
Breast Cancer
Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease
Ann Oncol
Curigliano G, Hu X, Dent R, Yonemori K, Barrios CH, Pierga JY, Puglisi F, Ferrero JM, Jung KH, Bagegni NA, Collignon J, Gil-Gil M, Wu X, Andrzejuk-Ćwik A, Schwaederle M, Anand S, Bardia A
doi: 10.1016/j.annonc.2026.02.015
CHICAGO 2026
Breast Cancer
NATALEE: Gene expression analysis supports ribociclib plus NSAI across PAM50 intrinsic subtypes in HR-positive, HER2-negative early breast cancer
SABCS 2025
Breast Cancer
DESTINY-Breast11: T-DXd followed by THP shows manageable and more favorable safety profile versus ddAC–THP in patients with high-risk HER2-positive early breast cancer
Breast Cancer
Chemotherapy duration and patient-reported outcomes in HER2-positive early breast cancer: Results from the TRAIN-3 study
Eur J Cancer
Louis FM, der Voort AV, Egeler MD, Ramshorst MSV, Mandjes IA, Kemper I, Agterof MJ, der Steeg WAV, Heijns JB, Bekkum MLV, Siemerink EJ, Kuijer PM, Scholten A, Wesseling J, Peeters MTV, Mann RM, de Poll-Franse LVV, Sonke GS, Dutch Breast Cancer Research Group (BOOG)
doi: 10.1016/j.ejca.2026.116882
SABCS 2025
Breast Cancer
DESTINY-Breast09: Favorable PROs with T-DXd plus pertuzumab in first-line HER2-positive advanced and metastatic breast cancer
SABCS 2025
Breast Cancer